Study reveals new targets to inhibit pulmonary fibrosis

October 5, 2018 by Paul Govern, Vanderbilt University
Study reveals new targets to inhibit pulmonary fibrosis
Wonder Drake, MD, seated, and colleagues, from left, Weifeng Luo, PhD, Lindsay Celada, PhD, Ozioma Chioma, PhD, and Kenny Abel are studying new ways to inhibit pulmonary fibrosis. Credit: Anne Rayner

In a study out this week in Science Translational Medicine, an international team led by researchers at Vanderbilt University Medical Center sheds new light on the cause of pulmonary fibrosis and demonstrates a way to impede the disease in mice.

The study results imply that certain drugs already at market might be able to be repurposed to inhibit or halt this major respiratory disease.

"I'm very excited by the implications of our study for drug repurposing and the important benefits that might accrue for a great many patients with lung disease," said Wonder Drake, MD, professor of Medicine and Pathology, Microbiology and Immunology, who led the study with Lindsay Celada, Ph.D., research instructor in Medicine.

"I'm doubly excited at the prospect of these clinical trials proceeding right here at VUMC. A combination of clinical investigative talent and research infrastructure makes VUMC the natural place to advance our lab's findings into the clinical realm."

People with pulmonary are perpetually short of breath. Connective tissue in their lungs has become thickened or scarred, reducing the supply of oxygen to the blood.

Fibrosis occurs in a number of diseases affecting the lungs, among them sarcoidosis and (IPF). Median survival with IPF is approximately three years. Pulmonary fibrosis can also occur in response to bleomycin, a drug in use since the 1960s to treat cancer.

Pursuing cues from an assortment of previous findings, the new study uncovers a common immunological mechanism underlying these three distinct disease types.

In both IPF and bleomycin-induced fibrosis, previous studies had indicated connections with a pro-inflammatory cell signaling protein called interleukin-17 (IL-17A). Meanwhile, people studying sarcoidosis had found dysfunction in a type of white blood cell, the CD4+ T cell.

Drake had traced this dysfunction to upregulation of PD-1, or programmed cell death protein 1, a that inhibits autoimmunity.

Fibroblasts are cells that produce the structural framework of animal tissues, including wound-healing tissues. IPF in particular has been shown to involve overactivation of .

The team placed normal lung fibroblasts in culture with CD4+ T cells harvested from people with IPF or sarcoidosis. Type 1 collagen production, a hallmark of fibrosis, results in both these cultures; but not so in the case of CD4+ T cells from patients with healthy lungs.

Employing an array of techniques and covering a lot of ground, the study introduces a causal story that starts with PD-1 upregulated CD4+ T cells, leading to increased expression of a gene transcription activator called STAT3, and then on to increased production of IL-17A, resulting in fibrosis.

"Though they haven't typically been considered important in pulmonary fibrosis, we're showing a central role in a range of diseases for CD4+ T cells with PD-1 upregulation," Celada said.

With its wide scope, the study brings attention to three potential drug targets for which drugs are already available: blocking PD-1 can significantly reduce fibrosis in mice, the team shows; using human in vitro, they show that chemical inhibition of STAT3 reduces components of fibrosis, such as collagen production; and finally, the study brings added attention to the role of IL-17A in sarcoidosis .

Explore further: Blocking the molecular source of idiopathic pulmonary fibrosis

More information: Lindsay J. Celada et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aar8356

Related Stories

Blocking the molecular source of idiopathic pulmonary fibrosis

May 8, 2018
Idiopathic pulmonary fibrosis (IPF) is one of the most challenging and frustrating diseases that pulmonologists face.

Pulmonary fibrosis caused by single transcription factor

December 26, 2017
To date, the molecular basis of pulmonary fibrosis has been poorly understood. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now shown that reduced activity of the transcription ...

Metformin reverses established lung fibrosis

July 2, 2018
Researchers at the University of Alabama at Birmingham have shown—for the first time—that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.

Vaccine improves fibrosis in mouse model of idiopathic pulmonary fibrosis

April 7, 2016
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease characterized by lung fibrosis and declining lung function. There are currently few effective treatments for IPF, and the median survival following diagnosis ...

Radiation and pulmonary fibrosis

November 16, 2017
Radiation-induced pulmonary fibrosis—tissue scarring that can permanently impair lung function—limits the delivery of therapeutic radiation doses to non-small cell lung cancer.

Recommended for you

Gene plays critical role in noise-induced deafness

October 19, 2018
In experiments using mice, a team of UC San Francisco researchers has discovered a gene that plays an essential role in noise-induced deafness. Remarkably, by administering an experimental chemical—identified in a separate ...

Functional engineered oesophagus could pave way for clinical trials 

October 18, 2018
The world's first functional oesophagus engineered from stem cells has been grown and successfully transplanted into mice, as part of a pioneering new study led by UCL.

New findings cast light on lymphatic system, key player in human health

October 16, 2018
Scientists at the Oklahoma Medical Research Foundation have broken new ground in understanding how the lymphatic system works, potentially opening the door for future therapies.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Age-related increase in estrogen may cause common men's hernia

October 16, 2018
An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 ...

Income and wealth affect the mental health of Australians, study shows

October 16, 2018
Australians who have higher incomes and greater wealth are more likely to experience better mental health throughout their lives, new research led by the Bankwest Curtin Economics Centre has found.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.